Hairy Cell Leukemia (HCL): Clinical Trials

6 trials for Hairy Cell Leukemia (HCL), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 2 completed, 1 not yet recruiting. 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 21Completed 1

Follow Hairy Cell Leukemia (HCL): new trials by email Literature Review of Hairy Cell Leukemia (HCL) trials Research Report on Hairy Cell Leukemia (HCL)

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies
Chronic Lymphocytic Leukemia (CLL), Splenic Marginal Zone Lymphoma
Not yet recruitingIRCCS San Raffaele642026-11-012026-08-13
Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management
Hairy Cell Leukemia (HCL)
RecruitingIRCCS Azienda Ospedaliero-Universitaria di Bologna502024-12-122025-01-14
Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care Management
Hairy Cell Leukemia (HCL)
RecruitingIRCCS Azienda Ospedaliero-Universitaria di Bologna502024-12-052025-01-08
Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
CompletedIRCCS Azienda Ospedaliero-Universitaria di Bologna1022022-02-212025-01-20
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL)
RecruitingNational Cancer Institute (NCI)12632010-03-022026-10-29
Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab
2CdA +/- Rituximab - Hairy Cell Leukemia (HCL)
Phase 2CompletedJurgen Barth892004-06-012024-08-22

Narrower conditions

Leukemia, Hairy Cell (6)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (3)  ·  Hemolytic-Uremic Syndrome (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)  ·  Lymphoma, Follicular (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphoma, T-Cell (1)  ·  Lymphoma, T-Cell, Cutaneous (1)  ·  Mycosis Fungoides (1)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)

Broader conditions

Hematologic Diseases (6)  ·  Hemic and Lymphatic Diseases (6)  ·  Immune System Diseases (6)  ·  Immunoproliferative Disorders (6)  ·  Leukemia (6)  ·  Lymphatic Diseases (6)  ·  Lymphoproliferative Disorders (6)  ·  Neoplasms (6)  ·  Neoplasms by Histologic Type (6)  ·  Chronic Disease (3)  ·  Disease Attributes (3)  ·  Leukemia, B-Cell (3)  ·  Leukemia, Lymphoid (3)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)

Interventions

Cladribine (1)  ·  Rituximab (1)

Sponsors

IRCCS Azienda Ospedaliero-Universitaria di Bologna (3)  ·  IRCCS San Raffaele (1)  ·  Jurgen Barth (1)  ·  National Cancer Institute (NCI) (1)

Countries

Italy (4)  ·  Germany (1)  ·  United States (1)

Top investigators

Lucia Catani, PhD (3)  ·  Mathias J Rummel, Prof. Dr. (1)  ·  Robert J Kreitman, M.D. (1)

Results publications

PMID 37729613, PMID 37877800, PMID 39719040, PMID 40552139